Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2022
Vaccine approval before Phase 3 trial results: a consequence of vaccine access inequity
2 March 2022 - The final Phase 3 clinical data for CanSino Biologics' adenovirus type 5 vector vaccine show that Ad5-nCoV ...
Posted by Michael Wonder on 08 Mar 2022
Saluda Medical receives FDA approval for the Evoke spinal cord stimulation system to treat chronic intractable pain
8 March 2022 - Evoke system deemed superior to open loop spinal cord stimulation in treating overall back and leg pain. ...
Posted by Michael Wonder on 08 Mar 2022
FDA effort to improve clinical trial diversity failed to make a difference for Black patients, study finds
7 March 2022 - Six years ago, the U.S. FDA launched a five year action plan to improve the diversity and ...
Posted by Michael Wonder on 08 Mar 2022
FDA offers funding for biosimilar regulatory science pilot
7 March 2022 - The US FDA is offering funding for several research proposals under the regulatory science pilot for ...
Posted by Michael Wonder on 07 Mar 2022
TGA approves Sogroya
8 March 2022 - Somapacitan is a long‑acting recombinant human growth hormone derivative. ...
Posted by Michael Wonder on 07 Mar 2022
Merit Medical receives FDA breakthrough device designation for Embosphere microspheres for use in genicular artery embolisation for symptomatic knee osteoarthritis
7 March 2022 - Merit Medical Systems announced today that it has received breakthrough device designation from the U.S. FDA ...
Posted by Michael Wonder on 07 Mar 2022
Key Democrat moves to crack down on FDA accelerated approvals
7 March 2022 - A powerful Democratic lawmaker has introduced a bill that would dramatically rein in the Food and ...
Posted by Michael Wonder on 07 Mar 2022
Teva announces launch of a first generic version of Revlimid (lenalidomide capsules) in the U.S.
7 March 2022 - Teva Pharmaceuticals announced today the launch of a first generic version of Revlimid (lenalidomide capsules), in 5 ...
Posted by Michael Wonder on 07 Mar 2022
Novavax’s Covid-19 vaccine moves closer to FDA authorisation decision
6 March 2022 - Company says it has resolved manufacturing problems that led to earlier delays; FDA is reviewing shot’s authorisation ...
Posted by Michael Wonder on 07 Mar 2022
Horizon Therapeutics announces FDA has granted priority review of the supplemental biologics license application for the concomitant use of Krystexxa (pegloticase injection) plus methotrexate for people living with uncontrolled gout
7 March 2022 - Application based on recent MIRROR randomised controlled trial results, which showed 71% of patients randomised to ...
Posted by Michael Wonder on 07 Mar 2022
Servier announces FDA filing acceptance and priority review for Tibsovo (ivosidenib tablets) in combination with azacitidine for patients with previously untreated IDH1 mutated acute myeloid leukaemia
7 March 2022 - sNDA based on data from the global, Phase 3, AGILE trial evaluating Tibsovo in combination with ...
Posted by Michael Wonder on 07 Mar 2022
Jardiance (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
7 March 2022 - The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with ...
Posted by Michael Wonder on 07 Mar 2022
ATAGI update following weekly COVID-19 meeting (2 March 2022)
7 March 2022 - As of 1 March 2022, over 54 million doses of COVID-19 vaccines have been administered in ...
Posted by Michael Wonder on 06 Mar 2022
Australian COVID nasal spray not on shop shelves amid TGA dispute
4 March 2022 - Melbourne start-up Starpharma is at loggerheads with the medicines regulator over the approvals process for its ...
Posted by Michael Wonder on 06 Mar 2022
U.S. Food and Drug Administration approves Opdivo (nivolumab) with chemotherapy as neo-adjuvant treatment for certain adult patients with resectable non-small cell lung cancer
4 March 2022 - Approval marks the first and only immunotherapy-based treatment for use before surgery for non-small cell lung cancer. ...